Opioid Induced Constipation
14
0
0
11
Key Insights
Highlights
Success Rate
85% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
14.3%
2 terminated out of 14 trials
84.6%
-1.9% vs benchmark
29%
4 trials in Phase 3/4
36%
4 of 11 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 11 completed trials
Clinical Trials (14)
Naloxegol Drug Utilization Post Authorisation Safety Study
Naloxegol Health Outcome Post Authorisation Safety Study
Real World Observational Study of Naloxegol for Patients With Cancer Pain Diagnosed With OIC.
Naloxegol US PMR CV Safety.
Prucalopride Effects on Subjects With Chronic Non-cancer Pain Suffering From Opioid Induced Constipation
A Study of TD-1211 in Subjects With Opioid-Induced Constipation (OIC)
A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Safety and Efficacy of TD-1211 in Subjects With Opioid-Induced Constipation
A Comparison of Oxycodone/Naloxone and Oxycodone After Laparoscopic Hysterectomy
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation
A Single-arm, Study to Assess the Effect and Tolerability of Standardised Laxative Therapy (SLT) for the Reversal of Opioid-induced Constipation (OIC).
Non-interventional Study Comparing Targiniq and Oxycodone/Laxatives
Open Label, Healthy Volunteers, Bioequivalence Study With Naloxegol
Naloxone SR Capsules in Patients With Opioid Induced Constipation